"MSD (Merck) is pursuing a systematic and thoughtful approach to expanding access to GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] in the developing world including a number of initiatives to study the public health impact of routine vaccination programs and to accelerate the introduction of vaccines in resource-poor countries.
In May 2010, Bhutan became the first developing nation in the world to implement a national cervical cancer vaccination program. MSD partnered with the government of Bhutan and the Australian Cervical Cancer Foundation (ACCF) to initiate a six-year program aimed at reducing incidences of the disease. The program, led by the Bhutan Ministry of Health, provided an opportunity for eligible girls and young women between the ages of 12 and 18 to be vaccinated with GARDASIL as part of this initiative. This partnership to provide HPV vaccination to all eligible girls completed its fourth successful year in 2013.
In April 2011, and through collaboration between the government of Rwanda, MSD and QIAGEN, the Rwanda Ministry of Health a launched a comprehensive national cervical cancer prevention program. Approximately 90,000 Rwandan girls were vaccinated with GARDASIL in the first year of the program, and, over the three-year program, Rwanda was supplied with enough doses to vaccinate over 450,000 girls.
In September 2012, the Republic of Uganda, through the Ministry of Health (MoH) and supported by MSD, launched a sub-national vaccination program with GARDASIL. Through this agreement, the vaccination program was implemented with nearly 500,000 doses of GARDASIL donated to 12 districts in Uganda, enough to vaccinate approximately 160,000 girls age 9 to 13 of age over a two year period. The program represented the first phase of Uganda’s national roll-out plan for human papillomavirus (HPV) vaccination.
Through the GARDASIL Access Program, launched in 2007, MSD has donated over 1.2 million doses of MSD's HPV vaccine to support the development of successful immunization programs in lowest income nations. The program has enabled applicants in 21 countries to gain operational experience in designing and implementing small-scale HPV vaccination projects. From Africa to Asia and Latin America, these experiences provided helpful information about the feasibility of HPV vaccine delivery in developing country settings. While vaccine doses are no longer being awarded, experiences and lessons learned are being disseminated in an effort to contribute to the public knowledge base on HPV vaccine access and child and adolescent immunization models.
*MSD is known as Merck in the U.S. and Canada"
|Location||East Asia and Pacific, Viet Nam, Vanuatu, Uzbekistan, Uganda, Tanzania, Peru, Papua New Guinea, Nicaragua, Nepal, Moldova, Lesotho, Kenya, India, Haiti, Ghana, Georgia, Cameroon, Cambodia, Bolivia, Bhutan, West Africa, Southern Africa, South Asia, Latin America and Caribbean, Eastern Africa, Central Asia, Central Africa|